Search Results
Dec 08, 2025, 08:00 ET Pierre Fabre Pharmaceuticals Announces Updated Phase 3 Tabelecleucel Data at American Society of Hematology Meeting in Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
positive post-transplant lymphoproliferative disease (EBV+ PTLD), NRAS-mutant melanoma, non-small cell lung cancer with mutation or amplification of MET, and X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED). Pierre Fabre Pharmaceuticals is headquartered in Parsippany, NJ.Pierre Fabre, Pierre
More news about: Pierre Fabre Pharmaceuticals
Dec 08, 2025, 07:00 ET iyO Secures Trademark Victory: Restraining Order Against Sam Altman, Jony Ive, and OpenAI Upheld
identity of an emerging innovator.The conflict stems from a fundamental dispute over identity and fair competition. In early 2022, iyO leadership met with the defendants to discuss iyO's vision: a future where human-machine interaction is driven by natural language rather than screens. At the time,
More news about: iyO, Inc.
Dec 08, 2025, 07:00 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
and adults with CDKL5 deficiency disorder (CDD) at the American Epilepsy Society (AES) meeting in Atlanta, December 5-9, 2025.1 The trial met its primary endpoint and two of the three key secondary endpoints, demonstrating a statistically significant reduction in countable motor seizure frequency
More news about: UCB
Dec 08, 2025, 05:00 ET Le gouvernement chinois exploite les universités britanniques pour faire progresser la technologie militaire
présentant un intérêt militaire évident, notamment les communications antibrouillage, l'hypersonique et le dépôt d'énergie dirigé par laser.Le rapport met en évidence une collaboration considérable avec les « sept fils de la défense nationale », un consortium d'universités de la RPC qui font partie intégrante
More news about: Strider Technologies, Inc.
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
multiple sites across the U.S. Three dose levels of ASC30 oral tablets were investigated (20 mg, 40 mg and 60 mg). At 13 weeks, all three doses of ASC30 met the primary endpoint compared to placebo, demonstrating statistically significant (p values < 0.0001 for 20 mg, 40 mg and 60 mg vs placebo)
More news about: Ascletis Pharma Inc.
Dec 08, 2025, 03:12 ET INSP Investors Have Opportunity to Lead Inspire Medical Systems, Inc. Securities Fraud Lawsuit with the Schall Law Firm
prepared for every aspect of the Inspire V launch, touting high demand in the market. In truth, the Company's Inspire V launch was disastrous and was met with weak demand. The Company ignored basic steps that help ensure the quick adoption of new devices by clinicians. Based on these facts, the Company's
More news about: The Schall Law Firm
Dec 08, 2025, 01:32 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
adults with CDKL5 Deficiency Disorder (CDD) at the American Epilepsy Society (AES) meeting, Atlanta, USA, December 5-9, 2025.1 The trial met its primary endpoint and key secondary endpoints, demonstrating a statistically significant reduction in countable motor seizure frequency (CMSF) and
More news about: UCB
Dec 08, 2025, 01:28 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
adults with CDKL5 Deficiency Disorder (CDD) at the American Epilepsy Society (AES) meeting, Atlanta, USA, December 5-9, 2025.1 The trial met its primary endpoint and key secondary endpoints, demonstrating a statistically significant reduction in countable motor seizure frequency (CMSF) and
More news about: UCB
Dec 07, 2025, 19:00 ET AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore
small molecule drug discovery through advanced automation.Prof. Damian O'Connell of the Experimental Drug Development Centre: "We first met ChemLex in 2023, and since then we've seen the company grow from a promising startup to a global innovator in AI and automation-driven chemical synthesis.
More news about: ChemLex
Dec 07, 2025, 19:00 ET AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore
small molecule drug discovery through advanced automation.Prof. Damian O'Connell of the Experimental Drug Development Centre: "We first met ChemLex in 2023, and since then we've seen the company grow from a promising startup to a global innovator in AI and automation-driven chemical synthesis.
More news about: ChemLex
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were treatment-naïve or were BTK inhibitor-naïve. Pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compared to ibrutinib (87.0% [95% CI, 82.90-90.44] versus 78.5% [95% CI, 73.73-82.85];
More news about: Eli Lilly and Company
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
trial is the first to test the superiority of this regimen to intensive induction chemotherapy, the current standard for fit patients."Our study met its primary endpoint, demonstrating that aza-ven improves event-free survival. It also leads to higher rates of overall response and composite complete
More news about: American Society of Hematology
Dec 07, 2025, 05:18 ET In Quebec: Janette Bertrand presenteert een progamma op haar 100ste!
mensen uitdagen, verlichten en samenbrengen. Op 100 jaar heeft Janette Bertrand niet alles gezegd of gehoord! Zij keert terug naar Télé-Québec met Janette - Les jeunes et la vieille, een nieuw programma waarin ze de microfoon reikt aan jongeren in een openhartige, gevoelige en
More news about: Société de télédiffusion du Québec
Dec 06, 2025, 11:50 ET La Fondation des prix Yidan met en relation les connaissances mondiales et l'expertise locale lors de son sommet phare annuel
content:https://www.prnewswire.com/news-releases/la-fondation-des-prix-yidan-met-en-relation-les-connaissances-mondiales-et-lexpertise-locale-lors-de-son-sommet-phare-annuel-302634633.html
More news about: Yidan Prize Foundation
Dec 06, 2025, 08:30 ET Advances in Technology Help Improve Safety and Access to Blood Cancer Therapies
evidence of measurable residual disease (MRD) through next-generation-sequencing (NGS) before starting the pre-transplant conditioning process. The trial met its primary endpoint with a two-year relapse-free survival rate comparable to that of an observational cohort of patients who received TBI-based conditioning."We
More news about: American Society of Hematology
Dec 06, 2025, 07:00 ET Research Reveals Avenues for Informing and Improving Sickle Cell Care
before organ damage accumulates – could make exa-cel even more beneficial in children than adults."All younger patients with sufficient follow-up met the primary endpoint of being transfusion independent in those with beta thalassemia and free of vaso-occlusive crises for those with sickle cell disease,"
More news about: American Society of Hematology
Dec 05, 2025, 17:45 ET AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
Primary safety and tolerability endpoint metAP-101 prolonged survival and delayed need for ventilatory support after 12 months of treatmentFunctional stabilization and reduced neurofilament biomarkers observed in study participants with elevated
More news about: AL-S Pharma AG
Dec 05, 2025, 16:45 ET Cui Li, CDO van ZTE, aan het woord op AI Innovation Asia 2025 georganiseerd door Economist Impact
niveau 4 en hoger met drie engines mogelijk: Nebula Telecom Large Model, big data en digital twin. In de praktijk hebben ZTE en China Mobile samen multi-agents ontwikkeld die netwerkproblemen kunnen detecteren en zelfherstel mogelijk maken, waardoor de tijd voor het oplossen van problemen met 47% wordt teruggebracht.Vraag
More news about: ZTE Corporation
Dec 05, 2025, 15:03 ET Cango Inc. maakt de bitcoin-productie en een update van de mijnbouwactiviteiten voor november 2025 bekend
AI-computernetwerk aangedreven door groene energie."Over Cango Inc.Cango Inc. (NYSE: CANG) houdt zich voornamelijk bezig met bitcoin-mijnbouw, met activiteiten die strategisch over Noord-Amerika, het Midden-Oosten, Zuid-Amerika en Oost-Afrika zijn verspreid. Het bedrijf stapte in november
More news about: Cango Inc.
Dec 05, 2025, 14:18 ET Nominatie van Mohammed Murad van PT Asset Management in Smith's 2025 All-Star Second Team als Buyside Director of Research
bijgedragen tot de reputatie van het bedrijf dankzij helderheid en overtuiging in vastrentende beleggingen."Gefeliciteerd Mo met deze prestigieuze award. Samen met zijn team heeft Mohammed een robuust platform opgezet dat PTAM helpt om de kredietdynamiek in het brede spectrum van gemeentelijke
More news about: PT Asset Management, LLC
Dec 05, 2025, 09:04 ET USMNT Stars Gio Reyna and Joe Scally Mentor International Soccer Academy Players at Borussia Mönchengladbach
International Soccer Academy (ISA) North American players met with U.S. Men's National Team (USMNT) and
More news about: International Soccer Academy
Dec 05, 2025, 09:00 ET Steward Partners Expands Footprint in Sarasota, Marking a New Chapter of Growth in the Southeast
background checks and interviews by Inc.'s research department, with a final vetting process by the editorial team to ensure ethical standards were met. As always, Inc. reserves the right to decline applicants for subjective reasons. Steward Partners nor its affiliates paid a fee to Inc. Magazine in
More news about: Steward Partners
Dec 05, 2025, 08:30 ET Sabre Corporation Announces Early Participation Results of the Previously Announced Exchange Offers for Certain Senior Secured Debt Securities and Extends the Related Early Exchange Premium through the Expiration Date
equals to $379 million (as such amount may be amended by Sabre GLBL in its sole discretion, the "2029 Notes Maximum Exchange Amount"), which has been met as of the Early Exchange Date.Sabre GLBL's obligation to accept for exchange the Existing Notes validly tendered and not validly withdrawn in
More news about: Sabre Corporation
Dec 05, 2025, 07:00 ET Otis New Equipment Project Wins Industry Award
reconstruction of this huge infrastructure project. With rigorous project management and effective communication with all stakeholders, they successfully met the complex construction schedules.The installation included moving walks measuring 125 meters, and two that measure 136 meters. These are Asia's
More news about: Otis Worldwide Corporation
Dec 05, 2025, 06:58 ET Cognizant verdubbelt inzet voor Synapse met een nieuw doel om twee miljoen te bereiken in 2030
te helpen gedijen in het door AI aangedreven tijdperk, zodat zij kunnen deelnemen aan de welvaart die deze digitale transformatie met zich meebrengt."Cognizant wil met het Synapse-initiatief een nieuwe standaard creëren voor werknemersgereedheid. Synapse doorbreekt sociaaleconomische, culturele
More news about: Cognizant